Company Overview
Snapshot
Founded in January 2015 by Ofer Nussbaum, Ph.D. and Boaz Musafia, AptuCure Bio operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on the development of novel therapeutic solutions.
Business overview
AptuCure Bio is a biotechnology company developing AptuBodies, which are synthetic aptamer-based nanoparticles designed to mimic antibody activity. These AptuBodies bind to the Fab fragment of circulating IgG antibodies, providing a new antigen binding domain targeted to specific cell surface markers. This mechanism allows the AptuBodies/IgG complex to activate the natural immune system, including the complement system and killer cells, to target and eliminate cells. AptuCure Bio's technology aims to replace humanized antibodies for treating cancer, infectious diseases, and autoimmune conditions within the pharmaceuticals and life sciences sectors.
Log in to access full profile ›Company Intelligence Q&A
- What is AptuCure Bio's core technology?
- AptuCure Bio is developing AptuBodies, which are unique synthetic aptamer-based nanoparticles designed to mimic antibody activity. These AptuBodies can be directed against virtually any target by binding to the Fab fragment of circulating IgG antibodies.
- What therapeutic areas is AptuCure Bio targeting?
- AptuCure Bio's AptuBody technology is being developed for the treatment of cancer, infectious diseases, and autoimmune diseases, aiming to provide alternatives to humanized antibodies.
- When was AptuCure Bio founded?
- AptuCure Bio was founded in January 2015.
- Who are the founders of AptuCure Bio?
- AptuCure Bio was founded by Ofer Nussbaum, Ph.D. and Boaz Musafia.
- What is the current product development stage for AptuCure Bio?
- AptuCure Bio is currently in the R&D stage for its AptuBodies technology, focusing on the development of novel therapeutic solutions for cancer, infectious diseases, and autoimmune conditions.